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Background: The aim of this study was to examine the association of a family history of 
cancer with the risk of testicular cancer in young adults. 
 
Methods: This is a prospective cohort study including 1,974,287 males born 1951-2015, of 
whom 2,686 were diagnosed with TC before the age of 30.  
 
Results: A history of TC in male relatives was significantly associated with a diagnosis of TC 
among children and young adults, including brothers(6.3-fold), sons(4.7-fold), fathers(4.4-
fold), paternal uncles(2.0-fold) and maternal uncles (1.9-fold). Individuals with a father 
diagnosed with a carcinoma or sarcoma showed an elevated risk (1.1-fold and 1.8-fold, 
respectively). A family history of mesothelioma was positively associated with a risk of TC 
[(father (2.8-fold), mother (4.6-fold) and maternal uncles and aunt (4.4-fold)]. Elevated risks 
were also observed when siblings were diagnosed with malignant melanoma (1.4-fold). The 
risk of TC was also increased when fathers (11.1-fold), paternal (4.9-fold) and maternal 
uncles and aunts (4.6-fold) were diagnosed with malignant neuroepithelial-tumours.  
 
Conclusion: We found an increased risk of TC among children and young adults with a 
family history of TC, carcinoma, mesothelioma, sarcoma, malignant melanoma and malignant 
neuroepithelial tumours. Hereditary cancer syndromes might underlie some of the 
















Germ-cell testicular cancer (TC) is the most common form of cancer in young males in 
industrialised countries. The global incidence of TC has more than doubled over the past 40 
years.1 Males born around 1943 and around 1968 in the Nordic countries are at lower risk of 
TC than men born before and after each of these dates, suggesting a birth-cohort effect in the 
incidence of TC.2  
 
The majority of TC derives from germ cells and can be divided into two major histologic 
types: pure classic seminoma and non-seminomatous germ cell tumours. These are believed 
to originate from a common precursor, the germ cell neoplasia in situ (GCNIS).3 
The aetiology of TC remains unknown. Rapid increases in TC incidence highlight the 
importance of investigating risk factors involved in the development of this cancer. The 
strongest risk factors are a family history of the disorder, a previously diagnosed TC, and 
cryptorchism.4,5,6,7,8,9 Prenatal and postnatal exposure to certain persistent environmental 
chemicals classified as endocrine disruptors have been reported to be associated with the risk 
of testicular cancer. However, the evidence is limited.10 Socio-economic differences in the 
incidence rates of TC have also been reported in the Nordic countries.11 
 
Cancer in children and young adults generally has more underlying genetic causes compared 
to cancer in older adults, who have decreased DNA repair capability and longer 
environmental exposure. In order to identify a young population with a possible inherited 
cancer predisposition syndrome, an accurate family history integrating information about the 
site of the origin of the cancer, as well as tumour characteristics such as cancer morphology in 
relatives, is essential. The most common malignancies associated with hereditary cancer 
syndromes include morphological types such as sarcomas, carcinomas, epitheliomas, 
glioblastomas, malignant melanomas and endocrine tumours, as seen in the Li-Fraumeni 
syndrome, Lynch syndrome, cutaneous malignant melanoma syndrome and multiple 
endocrine neoplasia.12 Consequently, we hypothesise that children and young adults with TC 
more frequently have relatives with common malignancies associated with hereditary cancer 
syndromes compared to children without TC.  
 
Previous studies into familial clustering of cancer have typically used organ-specific site 
classification rather than histological subtypes to examine the risk of TC.5,6,7,8,9 Insight into 
the association of familial clustering of cancers with TC, based on morphological cancer 
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groups, might contribute to the identification of individuals at increased risk of developing the 
disorder, and might also increase our understanding of this cancer.  
 
The aim of this study was to examine the association of a family history of cancer, evaluating 
the impact of both morphological groups as well as organ of origin, with the risk of TC in 
children and young adults. We took advantage of the close to complete population-based 
registries in Norway that contain uniform and continuously updated information on childbirth, 
familial relationship, cancer incidence and vital status. 
 
Materials and methods 
Study population 
All males born in Norway from 1951 to 2015 were included in the study. Information on 
these individuals and their first-degree relatives, uncles and aunts was obtained from the 
Central Population Register of Norway which has information on the relationship between 
each individual and his/her relatives.13,14 Information on first degree relatives for each 
individual is almost complete for individuals born in Norway since 1950. We identified 
cancer among all included males and their relatives through linkage to the Norwegian Cancer 
Registry using Norwegian personal identification numbers. 
 
Cases or index persons were all males registered in the Norwegian Cancer Registry who had 
been diagnosed with TC before the age of 30 years between 1951 and 2015. TC was classified 
into seminomas and non-seminomas using the International Classification of Diseases for 
Oncology (ICDO-3) and topography (C62).15 Unclassified TC (n=271) was excluded from the 
analyses. 
 
Cancer among relatives  
Morphological groups were classified according to the World Health Organization’s 
morphologic classification of human cancer into seven main groups: carcinomas, sarcomas, 
mesotheliomas, tumours of the hematopoietic and lymphoid tissues, Kaposi sarcomas, other 
specified cancer types, and unspecified types of cancer (Supplementary Table 1).15,16  Kaposi 
sarcomas, some unspecified types of cancer and some morphological subgroups were 




A separate analysis of the major morphological groups was also conducted using the organ of 
origin of the cancer in relatives.  Analyses of cancer were conducted among relatives based on 
the anatomic site (topography) of the body in which the cancer originated using the 
International Statistical Classification of Diseases and related health problems (ICD-10).17 To 
reduce the width of our confidence intervals and to increase precision, ICD-10 codes for 
which at least two relatives of the index persons diagnosed with cancer were identified were 
included. This strategy was applied to all the analyses. The following organs and codes were 
considered: Lip, oral cavity and pharynx (C00-C14), oesophagus (C15), stomach (C16), colon 
(C18), rectum (C20), pancreas (C25), lung (C34), skin (C43–C44), breast (C50), cervix uteri 
(C53), Corpus uteri(C54), ovary (C56), prostate (C61), kidney (C64), ureter (C66), bladder 
(C67) and thyroid (C73). 
 
Other variables 
Families might have different socioeconomic status and levels of environmental exposure that 
could potentially confound our findings. Models were adjusted for mother or father’s 
education. Adjustments for the number of family members were also made to account for the 
difference in family size. Information on parent’s educational level was obtained from 
Statistics Norway and was categorised into five subgroups according to the International 
Standard Classification of Education: primary education (<10 years), secondary education and 
tertiary vocational education (10-14 years), and higher education (equivalent to bachelor, 
master or PhD).18 To control for birth-cohort effects reported in other studies, adjustments 
were made for year of birth.19 
 
Statistical analysis 
Cox proportional hazard regression was used to estimate the association between the 
incidence of cancer in relatives and risk of TC. Testicular cancer in a child or young adult was 
the dependent variable and cancer in relatives the explanatory variable. Age was used as time 
scale. The follow-up period for each child and young adult was from birth to the age of cancer 
diagnosis, with censoring at the age of 30 years, death, emigration or end of study. All 
analyses were adjusted for number of relatives (continuous variable), according to which 
relative was examined.  
 
The risk of TC according to the relationship of the cancer-affected relatives was examined to 
determine whether there were differences in risk according to kinship. The hazard ratio (HR) 
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and 95% confidence intervals (CI) for morphological types are presented separately for father, 
mother, siblings, paternal uncles and aunts, and maternal uncles and aunts. Risk estimates for 
cancer by ICD-10 subtypes included groups of relatives: parents, siblings and both paternal 
and maternal uncles and aunts. These last analyses were conducted separately for seminomas 
and non-seminomas.  Due to the limited number of cases diagnosed with TC before the age of 
15 years, data for the whole population were presented. Offspring of the index person were 
not included because of the low number of cancer cases found in this group. The proportional 
hazards assumption was verified by plotting Schoenfeld residuals.  
 
All analyses were performed using SPSS version 25 (IBM, Armonk, NY, USA).  
 
Results 
A total of 1,974,287 males born between 1951 and 2015 were followed for risk of TC. During 
this period 2,686 index persons were diagnosed with TC (Table 1). The majority of cases 
were diagnosed with non-seminomas. Index persons diagnosed with seminomas were slightly 
older compared with non-seminomas (Table 1 and Figure 1). Most of the study population 
had information on variables included in the analysis for mother (99.4%) and father (98. 
1%).The associations between a family history of cancer and risk of TC were similar before 
and after adjustment for covariates; adjusted results are reported. 
 
Cancer family history across morphological groups 
Associations of risk of TC with a family history of cancer (all cancer subtypes) were observed 
for multiple relationships and morphological groups (Table 2). Statistically significant 
associations were observed for index persons where fathers and maternal uncles and aunts 
were diagnosed with carcinomas HR=1.11 (1.00-1.23) and HR=1.15 (1.02-1.30), respectively, 
particularly the subtype adenocarcinoma. The risk of TC was also elevated when fathers were 
diagnosed with sarcomas HR=1.81 (1.10-2.96).  
 
A family history of mesothelioma was associated with the risk of TC. The risk increased 
when father, mother, or maternal uncles and aunts of index persons were diagnosed with 





Overall, the risk of TC was associated with a family history of TC in male relatives (Figure 
2). The highest risk was noted among index persons with a brother with TC (6-fold increased 
risk), followed by individuals with a son or father diagnosed with testis cancer (4-fold 
increased risk). Statistically significant results were also observed for paternal and maternal 
uncles (Figure 2). The highest risk was observed among index persons with brothers 
diagnosed with TC type non-seminomas HR=8.24 (6.15-11.04). Among siblings the risk was 
also elevated for malignant melanoma HR=1.45 (1.01-2.06).  
 
A positive family history of malignant neuroepithelial tumours was also associated with an 
increased risk of TC. The elevated risk was observed among index person with an affected 
father and paternal and maternal uncles and aunts HR=11.15 (2.78-44.57); HR=4.92 (1.23-
19.70) and HR=4.62 (1.15-18.50), respectively.  
 
Cancer family history of cancer by cancer site 
The risk of developing TC among index persons increased overall when parents were 
diagnosed with squamous cell carcinoma of the lung (Table 3) and significantly increased for 
non-seminomas HR=1.58 (1.01-2.46), but not significantly for seminomas. A maternal 
diagnosis of cervical cancer increased the risk of seminoma among index persons HR 1.92 
(1.00-3.72). Index persons with a sister diagnosed with breast cancer of type adenocarcinoma 
had an elevated risk of TC HR=2.00 (1.24-3.21).  
 
A positive family history of urothelial carcinoma among uncles and aunts was associated with 
an elevated risk of TC in index persons HR=3.15 (1.01-9.81) (Supplementary Table 2).  
Cancer of other organs showing elevated risk of TC was found among index persons with 
uncles and aunts diagnosed with stomach cancer of type adenocarcinoma HR=2.38 (1.14-
4.95) (Supplementary Table 2). 
Elevated risk was also observed in index persons with siblings affected by other types of 
cancer, excluding carcinomas HR=1.87 (1.59-2.21). 
 
Discussion 
This population-based cohort study suggests that there is a significantly elevated risk of TC 
among individuals with a family history of cancer that extends beyond TC. Elevated risks 
were observed for family history of carcinoma, mesothelioma, sarcomas, testicular germ 
tumours, malignant melanoma and malignant neuroepithelial tumours. Such findings of 
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elevated risks among these morphological groups, with the exception of germ cell tumours 
and melanoma in a large population study, have not been previously reported. 
 
An increased risk of developing TC in males with first-degree relatives diagnosed with TC is 
consistent with previous studies.5,6,7,8,9 We also found an elevated risk of TC among index 
persons with paternal and maternal uncles diagnosed with TC (Figure 2). A recent study 
reported elevated risk of TC with a family history of breast cancer, melanoma, lung cancer 
and cancer in the central nervous system.20 
 
Human testicular cancer susceptibility genes have not yet been identified. The putative gene 
mapped to Xq27 is postulated to confer an increased risk of TC as well as cryptorchism.21 
Cancer is recognised as a disease that result from gradual accumulation of somatic mutations 
in the genome.22 The mutation frequency in the whole genome between generations of 
humans (parent to child) is about 70 new mutations per generation.23 Carcinomas, however, 
have much higher mutation frequencies.24 The high mutation frequencies in carcinomas reflect 
the genome instability characteristic of cancer. New results from the Cancer Genome Atlas 
Research Project have identified genetic mutations that are common among 12 different types 
of cancer, including carcinomas, adenocarcinomas and melanomas. This reflects the growing 
understanding that tumours can be defined by their underlying biology rather than their 
location in the body.25 Our results provide evidence of an increased familial risk of TC 
associated with a general family history of cancer; especially perhaps subtypes squamous cell 
carcinoma, urothelial carcinoma and adenocarcinoma. In an analysis of carcinomas by organ 
site, elevated risks were found for the lung, breast, cervix, ureter and stomach. Squamous cell 
carcinoma of the lung accounts for around 30% of all lung cancer. Although this histological 
subtype has a stronger association with smoking than any other type of lung cancer, family 
history and exposure to asbestos or radon are also risk factors for this type of cancer. 
 
The association between a family history of mesothelioma and TC in young TC patients has 
not been previously reported. A particularly striking finding in the present study was the 
significant increase in the risk of TC among index persons with parents and uncles and aunts 
with mesothelioma. The increased risk was consequent for both seminoma and non-
seminoma. However, the analyses are based on a small number of cases. Travis and 
colleagues reported statistically significantly increased risk of malignant mesothelioma (3.4-
fold) in TC survivors.26 They concluded that the treatment of cancer patients with very high 
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doses of radiation, or the impact of the natural history of the disease might explain the 
observed excess risk.  
 
Heritable mutations in the BAP1 tumour suppressor gene predispose individuals to 
mesothelioma and other forms of cancer. The BAP1 tumour predisposition syndrome is a 
novel cancer syndrome characterised by onset at an early age of melanomas and, later in life, 
by a high incidence of mesothelioma, melanoma and renal cell carcinoma.27,28,29,30 The full 
spectrum of this syndrome is still being characterised through the discovery of new associated 
tumours, including cutaneous squamous cell carcinoma,31 basal cell carcinoma,32,33 lung 
adenocarcinoma,34 oesophageal adenocarcinoma,35 breast cancer,36 rhabdoid meningioma,37 
neuroendocrine tumours,38 and certain types of sarcoma.39,40 Some types of cancer associated 
with this syndrome may also have a poor prognosis. In the present study, significant 
associations of TC were identified with a cancer family history of cancers related to the BAP1 
tumour predisposition syndrome, including mesothelioma, melanoma, squamous cell 
carcinomas, adenocarcinomas, sarcomas and breast cancer. 
 
Excess familial risk was also identified in other morphological groups, sarcomas, malignant 
melanoma, testicular germ cell tumours and malignant neuroepithelial tumours. Familial 
clustering of two or more cancer sites is usually attributed to specific, rare and dominantly 
inherited susceptibility genes. The increased risk of TC we found in index persons with male 
relatives with TC would support this theory. Some families are afflicted by a well-known rare 
inherited syndrome which frequently includes sarcomas, for example, as seen in the Li-
Fraumeni syndrome. Hereditary melanomas can appear as part of a Familial Melanoma 
Syndrome or a Mixed Cancer Syndrome.41 Usually this occurs by mutations in the CDKN2A 
gen. This syndrome not only increases the risk of melanoma but also other malignancies, such 
as sarcomas, lymphomas, cancer of the pancreas, lung, breast, cervix, ovary, stomach colon, 
brain and urinary bladder.  
 
Retinoblastoma, neuroblastoma, ganglioglioma and neuroepithelioma are among the most 
common neuro-epitheliomatous neoplasms. These cancers are associated with several 
hereditary cancer syndromes such as hereditary retinoblastoma, where sarcomas are the most 
frequent second cancer. Additional cancers found in this syndrome include leukaemia, 
lymphoma, melanoma, lung and bladder cancer.14 Neuroblastoma is also a feature of 




The results of the present study taken together with the results of other studies suggest that 
hereditary cancer syndromes could be involved in a predisposition to TC in young males. 
However, these findings do not exclude a possible influence of shared environmental factors 
among family members. Further research is needed to clarify the molecular genetic basis of 
testicular cancer and to identify potential susceptibility genes playing a role in the aetiology of 
the disease. More research is also needed to assess the possible interplay between 
environmental factors and genetic susceptibility in cancer causation. A better understanding 
of testicular cancer predisposition and biology will lead to further refinements in the clinical 
management of the disease, especially regarding identification of individuals of higher risk. 
 
The present study has several strengths. It is based on all births in Norway from 1951 to 2015. 
Thus, bias caused by a skewed study sample is unlikely. Information on the variables of 
interest was obtained from the linkage of national population-based registers (removing 
ascertainment and recall bias), and the high quality of cancer case registration permitted a 
complete follow-up of the study population. Data from the Norwegian Cancer Registry is 
considered reasonably accurate and close-to-complete.42 
 
The study also has some limitations. The present study is a registry-based study, with no 
access to biological samples for genetic analyses. Information on cancer risk among parents at 
a young age in the first birth cohort period was not available and could introduce bias by left 
truncation. The follow-up for cancer among relatives was until 2015. This could introduce 
bias. Parents and other first-degree relatives of children and young adults are often young, and 
cancer may not have developed yet. As noted, the number of cancer cases observed among the 
offspring of index cases was insufficient to include these relationships in the study. However, 
both of these sources of bias would lead to an underestimation of the actual cancer risk. 
Although this is a large cohort study some of these associations were based on small numbers 
which, might lead to some false positive results. Thus, the results are best considered together 
with those from similar studies. The study is based on children from Norway, primarily a 
white population. It is unclear whether these data can be generalised to non-Caucasian 
populations. Finally, this study should be considered to be hypothesis generating due to the 





We found significantly elevated risks of TC among children and young adults with a family 
history of testicular cancer, carcinomas, mesothelioma, sarcomas, malignant melanoma and 
malignant neuroepithelial tumours. 
 
Our results show that many of the cancers identified in the relatives of TC cases are found to 
be associated with the spectrum of several known cancer syndromes, such as cancers 
observed in BAP1 tumour predisposition syndrome, Li-Fraumeni syndrome, Familial 
Melanoma Syndrome, neurofibromatosis and hereditary retinoblastoma. Other syndromes 
cannot be excluded. However, the present study contains multiple comparisons and the results 
must be interpreted with caution. Further research into the genetic and environmental 
interactions associated with the risk of TC is critically important. 
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Figure 1. Age distribution of children and young adults <30 years born in Norway during 1951-2015 and who were 




Black and white 
 
Figure 1. Age distribution of children and young adults <30 years born in Norway during 1951-2015 and who were 












































Figure 2. Adjusted hazard ratios (95% confidence interval) for the association of family history of testicular cancer in 
first-degree relative’s males and uncles with risk of testicular cancer in children and young adults <30 years born in 
Norway during 1951-2015. 
The model was adjusted for child’s birth year and number of relatives according to type analysis. The model for father and 
brothers was also adjusted for mother or father’s education. 
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Table 1. Descriptive characteristics of a population-based cohort of male children and young adults <30 
years born in Norway during 1951-2015. 
Variable Cases Non-cases 
 No. % No. % 
 Total= 
2,686 
0.1 1,971,601 99.9 
Tumour histology     
   Seminoma 761 28.3   
   Non-seminoma 1654 61.6   
   Unclassified 271 10.1
Mean age at cancer diagnosis (SD)     
  All cases 24 (4.9)    
  Seminoma 26 (3.1)    
  Non-seminoma 23 (5.2)    
Mother’s education (years)     
<10 919 34.2 267,137 28.8 
10-14 1264 47.1 700,203 35.5 
>14 474 17.6 395,912 20.1 
Missing 29 1.1 308,349 15.6 
Father’s education (years)     
<10 726 27.0 475,844 24.1 
10-14 1332 49.6 783,268 39.7 
>14 560 20.8 377,921 19.2 
Missing 68 2.5 334,568 17.0 
Mean age at cancer diagnosis of the 
relatives (SD)  
 
Mean (SD)  
 
Mean (SD) 
   Father 668 64.1 (12.4) 338,567 66.1 (13.1) 
   Mother 538 61.2 (13.9) 288,954 61.7 (14.9) 
   Brothers 166 39.7 (16.0) 64,941 47.1 (16.9) 
   Sisters 121 43.4 (13.5) 70,820 45.4 (14.3) 
   Sons 14 17.6 (8.5) 5,261 18.6 (11.5) 
   Daughters 8 14.0 (10.8) 5,102 20.8 (12.0) 
   Paternal uncles 221 59.8 (14.3) 120,627 57.9 (15.3) 
   Paternal aunts 194 54.8 (13.5) 109,509 53.2 (14.4) 
   Maternal uncles 240 57.3 (13.5) 107,971 56.3 (15.6)
   Maternal aunts 204 54.7 (12.0) 103,467 52.1 (14.4) 
SD= Standard deviation 
 
Table 2. Adjusted hazard ratios (95% confidence interval) for family history of cancers by morphologic groups and risk of testis cancer among children and young 
adults <30 years born in Norway during 1951-2015. 
 
  FATHER MOTHER SIBLINGS FATHERS SIBLINGS MOTHERS SIBLINGS
Morphologic groups in relatives N HR (95% CI) N HR (95% CI) N HR (95% CI) N HR (95% CI) N HR (95% CI) 
Carcinomas 496 1.11 (1.00-1.23) 416 1.10 (0.98-1.22) 119 0.91 (0.75-1.11) 311 0.98 (0.86-1.11) 343 1.15 (1.02-1.30) 
   Squamous cell carcinoma 67 1.15 (0.90-1.47) 55 1.14 (0.87-1.50) 16 0.91 (0.55-1.49) 26 0.63 (0.43-0.93) 46 1.17 (0.87-1.57) 
   Urothelial carcinoma 39 1.06 (0.77-1.46) 14 1.29 (0.76-2.19) 4 0.76 (0.29-2.04) 15 0.87 (0.52-1.45) 18 1.11 (0.70-1.77) 
   Adenocarcinoma 343 1.13 (1.01-1.27) 295 1.04 (0.92-1.18) 97 1.00 (0.81-1.23) 238 1.04 (0.91-1.20) 250 1.20 (1.05-1.37) 
Other specific carcinomas 35 1.28 (0.91-1.79) 31 1.32 (0.93-1.89) 6 0.64 (0.29-1.44) 19 0.90 (0.57-1.41) 25 1.18 (0.79-1.75) 
   Neuroendocrine carcinoma 7 1.41 (0.67-2.97) 1.70 (0.85-3.40) 5 1.72 (0.71-4.13) 4 0.86 (0.32-2.29) 4 0.84 (0.31-2.24) 
Sarcomas and soft tissue tumours 16 1.81 (1.10-2.96) 12 1.36 (0.77-2.39) 8 0.95 (0.47-1.90) 11 1.11 (0.61-2.01) 6 0.60 (0.27-1.34) 
Mesothelioma 8 2.77 (1.38-5.56) 2 4.62 (1.16-18.50) - NC - NC 5 4.44 (1.85-10.70) 
Tumours of hematopoietic and lymphoid tissues 50 0.99 (0.75-1.31) 37 1.00 (0.72-1.38) 24 0.99 (0.66-1.48) 45 1.17 (0.87-1.58) 41 1.13 (0.83-1.54) 
   Myeloid 5 0.57 (0.24-1.38) 5 0.74 (0.31-1.77) 2 0.45 (0.11-1.82) 4 0.60 (0.23-1.61) 8 1.19 (0.60-2.39) 
   B-cell neoplasms 34 1.17 (0.83-1.64) 26 1.19 (0.80-1.75) 15 1.58 (0.95-2.62) 28 1.29 (0.89-1.87) 21 0.99 (0.65-1.53) 
       Non-Hodgkin lymphoma 12 0.87 (0.49-1.53) 17 1.49 (0.93-2.41) 8 1.45 (0.72-2.90) 17 1.41 (0.88-2.28) 12 1.04 (0.59-1.83) 
       Multiple myeloma and other plasma cell 12 1.32 (0.75-2.33) 5 0.77 (0.32-1.85) 3 1.59 (0.51-4.95) 7 1.23 (0.59-2.58) 5 0.93 (0.39-2.25) 
   Hodgkin lymphoma 4 1.42 (0.53-3.80) - NC 2 0.46 (0.12-1.86) 4 1.30 (0.49-3.48) 3 0.90 (0.29-2.79) 
   Malignant melanoma 21 0.66 (0.43-1.01) 35 1.08 (0.77-1.50) 31 1.45 (1.01-2.06) 23 0.75 (0.50-1.14) 37 1.22 (0.88-1.69) 
   Seminoma (C62) 22 4.45 (2.92-6.77) - NC 25 3.75 (2.52-5.56) 8 1.89 (0.94-3.78) 6 1.20 (0.54-2.67) 
   Non-seminoma (C62) 10 4.50 (2.42-8.37) - NC 46 8.24 (6.15-11.04) 6 2.37 (1.06-5.30) 8 2.87 (1.43-5.76) 
   Gliomas (C71) 4 0.41 (0.15-1.10) 6 0.90 (0.40-2.01) 9 1.14 (0.59-2.19) 5 0.57 (0.24-1.38) 3 0.35 (0.11-1.07) 
   Meningiomas 4 1.12 (0.42-2.99) 11 1.12 (0.62-2.02) 4 1.04 (0.39-2.77) 4 0.61 (0.24-1.64) 5 0.79 (0.33-1.90) 
   Malignant neuroepithelial tumours 2 11.15 (2.78-44.57) - NC 2 1.61 (0.40-6.45) 2 4.92 (1.23-19.70) 2 4.62 (1.15-18.50) 
The model was adjusted for child’s birth year and number of relatives according to type analysis. The model for parents and sibling was also adjusted for mother or father’s education. 
Cases: number of cancer cases with relatives affected. 
NC: children with <2 relatives diagnosed with cancer estimates were no calculated. We included morphologic groups were we find at least 2 relatives of the index persons diagnosed with cancer. 
 
Table 3. Adjusted hazard ratios (95% confidence interval) for family history of carcinomas by the most common subtypes among parents, siblings, uncles and 
aunts, and risk of testis cancer among children and young adults <30 years born in Norway during 1951-2015. 
 Parents Siblings 
 All cases Seminoma Non-seminoma All cases Seminoma Non-seminoma 
Type carcinoma in relatives N HR (95% CI) N HR (95% CI) N HR (95% CI) N HR (95% CI) N HR (95% CI) N HR (95% CI)
Squamous cell carcinoma             
   Lips, oral cavity and pharynx 14 0.93 (0.55-1.57) 4 0.93 (0.35-2.48) 10 1.14 (0.61-2.12) - NC - NC - NC 
   Lung 32 1.41 (1.00-2.00) 7 1.09 (0.51-2.29) 20 1.58 (1.01-2.46) - NC - NC - NC 
   Skin 35 1.00 (0.72-1.42) 9 0.89 (0.46-1.72) 23 1.19 (0.78-1.79) 4 1.41 (0.53-3.77) - NC - NC 
   Cervix uteri 21 1.26 (0.82-1.94) 9 1.92 (1.00-3.72) 10 1.01 (0.54-1.88) 6 0.89 (0.40-1.98) 3 1.59 (0.51-4.94) 3 0.78 (0.25-2.43) 
Urothelial carcinoma             
   Ureter 2 1.48 (0.37-5.91) - NC 2 2.69 (0.67-10.8) - NC - NC - NC 
   Bladder 47 1.10 (0.83-1.48) 10 0.82 (0.44-1.53) 30 1.25 (0.87-1.79) 4 0.86 (0.32-2.29) - NC - NC 
Adenocarcinoma             
   Esophagus 6 1.60 (0.72-3.56) 2 1.84 (0.46-7.37) 3 1.36 (0.44-4.23) - NC - NC - NC 
   Stomach 26 1.12 (0.76-1.65) 10 1.53 (0.82-2.87) 12 0.93 (0.52-1.64) - NC - NC - NC 
   Colon 91 1.10 (0.89-1.35) 28 1.16 (0.79-1.70) 50 1.05 (0.79-1.40) 10 1.01 (0.54-1.88) 2 0.73 (0.18-2.85) 6 1.13 (0.51-2.53) 
   Rectum 45 1.08 (0.88-1.34) 15 1.25 (0.75-2.10) 24 1.02 (0.68-1.52) 9 1.50 (0.78-2.90) 2 1.23 (0.31-4.93) 5 1.55 (0.64-3.73) 
   Pancreas 23 1.25 (0.83-1.90) 4 0.75 (0.28-2.00) 14 1.34 (0.79-2.27) 2 0.89 (0.22-3.55) - NC  - NC 
   Lung 31 0.97 (0.68-1.38) 8 0.86 (0.43-1.73) 16 0.86 (0.53-1.42) 5 1.08 (0.45-2.59) 2 1.60 (0.40-6.45) 2 0.81 (0.20-3.24) 
   Breast (female) 123 1.04 (0.87-1.25) 27 0.78 (0.53-1.14) 72 1.02 (0.81-1.30) 42 1.28 (0.94-1.75) 18 2.00 (1.24-3.21) 18 1.01 (0.63-1.60) 
   Cervix uteri 2 0.77 (0.19-3.08) - NC 2 1.26 (0.31-5.04) - NC - NC 0 NC 
   Corpus uteri 21 0.92 (0.60-1.41) 10 1.48 (0.79-2.77) 6 0.46 (0.21-1.02) - NC - NC - NC 
   Ovary 19 1.05 (0.67-1.66) 4 0.76 (0.28-2.04) 11 1.06 (0.59-1.92) 4 1.09 (0.41-2.91) 3 2.97 (0.95-8.99) - NC 
   Prostate 179 1.14 (0.97-1.33) 56 1.21 (0.92-1.60) 98 1.08 (0.88-1.33) 16 0.94 (0.57-1.54) 5 1.09 (0.45-2.56) 7 0.79 (0.37-1.67) 
   Kidney 26 1.10 (0.75-1.62) 7 1.03 (0.49-2.16) 14 1.01 (0.60-1.72) 3 0.59 (0.19-1.85) - NC 2 0.73 (0.18-2.93) 
   Thyroid 12 1.25 (0.71-2.20) 4 1.45 (0.54-3.87) 7 1.19 (0.57-2.49) 3 0.68 (0.22-2.12) - NC 2 0.80 (0.20-3.21) 
   No carcinomas 2399 0.88 (0.78-1.00) 674 0.83 (0.66-1.05) 1497 0.94 (0.80-1.11) 158 1.87 (1.59-2.21) 44 1.85 (1.36-2.52) 94 1.95 (1.58-2.41) 
The model was adjusted for child’s birth year and number of relatives according to type analysis. The model for parents and sibling was also adjusted for mother or father’s education. 
N: number of cancer cases with relatives affected. 
NC: children with <2 relatives diagnosed with cancer estimates were no calculated. We included the ICD-10 codes were we find at least 2 relatives of the index persons diagnosed with cancer. 
 
